Indirect comparison of three phase III trials in ER-positive, HER2-negative advanced breast cancer: imlunestrant plus abemaciclib showed numerically better PFS than fulvestrant plus abemaciclib (HR 0.77-0.83), not significant and not powered for testing.
RCT
Jhaveri et al. Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials